发明名称 Treatment of retroviral reservoirs exploiting oxidative stress
摘要 Activation of HIV-1 replication causes oxidative stress, which in turn potentiates HIV-1 replication. The common basis for the compounds of the present invention is: A) the capacity of reactivating HIV-1 from latency, and B) the ability to counteract the cellular machinery which activates in order to limit the effects of oxidative stress. In this way, oxidative stress can be potentiated and a “chain reaction” is sparked. This “chain reaction” induces a more efficient reactivation of HIV-1 from latency and, in some cases, induces selective killing of the infected cells. Actions A) and B) can either be carried out by one drug exerting both effects, or obtained by the combined use of distinct drugs. There are two main cellular machineries counteracting oxidative stress, i.e. the thioredoxin (Trx) thioredoxin reductase (TrxR) system and glutathione. Herein, we present drug strategies capable of exerting action B) by blocking either of the two machineries.
申请公布号 US8785493(B2) 申请公布日期 2014.07.22
申请号 US200913125325 申请日期 2009.10.29
申请人 Istituto Superiore di Sanita 发明人 Savarino Andrea;Mai Antonello;Palamara Anna Teresa;Garaci Enrico
分类号 A61K31/28;A61K31/70;A61K33/24 主分类号 A61K31/28
代理机构 Fish & Richardson P.C. 代理人 Fish & Richardson P.C.
主权项 1. A method for selectively targeting a cell latently infected with human immunodeficiency virus (HIV), which method comprises contacting a cell with auranofin in an amount effective for inducing replication of the latent HIV, wherein the auranofin has an epigenetic effect on the latently infected cell.
地址 Rome IT